The study, published March 13 in the Journal of Clinical Oncology, followed 55 patients with testicular seminoma across 12 institutions in the U.S. and Canada. Patients all had clinically low-volume retroperitoneal lymphadenopathy with a medium follow-up of 33 months.
Surgery was associated with a high recurrence-free survival rate and few complications. Four patients experienced short-term complications and four patients experienced long-term complications. Only 12 patients experienced recurrence, with a two-year recurrence-free survival of 81 percent. Of patients with a recurrence, 10 were treated with chemotherapy and two underwent additional surgery. At the last follow-up, all patients with recurrences were disease-free.
“We found that the majority of participants in the study were cured with surgery alone, avoiding the toxicities associated with traditional therapies,” lead investigator Sia Daneshmand, MD, a urologic oncologist at Keck Medicine of the University of Southern California in Los Angeles, said in a news release. “We are confident that surgery for this disease state will be included into treatment guidelines in the near future.”
Leave a Reply